

## 1. SYNONYMS

**CFR:** 3,4-Methylenedioxyamphetamine (MDMA)

**CAS #:** Base: 42542-10-9  
 d,l-MDMA: 69610-10-2  
 Hydrochloride: 64057-70-1  
 d,l-MDMA Hydrochloride: 92279-84-0

**Other Names:** N,  $\alpha$ -dimethyl-1,3-benzodioxole-5-ethanamine  
 N-methyl-3,4-methylenedioxyphenylisopropylamine  
 Methylenedioxyamphetamine  
**MDM,**  
**MDMA**  
 Ecstasy  
 E  
 XTC  
**Adam**  
**Clarity**  
**Elaine**  
**Essence**  
**Euphoria**

## 2. CHEMICAL AND PHYSICAL DATA

### 2.1. CHEMICAL DATA

Form	Chemical Formula	Molecular Weight	Melting Point (°C)
Base	C <sub>11</sub> H <sub>15</sub> NO <sub>2</sub>	193.2	<b>Oil</b>
Hydrochloride	C <sub>11</sub> H <sub>15</sub> NO <sub>2</sub> ·HCl	229.7	147-153
Phosphate	C <sub>11</sub> H <sub>15</sub> NO <sub>2</sub> ·H <sub>3</sub> PO <sub>4</sub>	<b>291.24</b>	<b>184-185</b>

## 2.2. SOLUBILITY

Form	A	C	E	H	M	W
Base	***	S	S	S	S	I
Hydrochloride	SS	S	I	***	S	S
Phosphate	I	I	I	I	S	VS

A = acetone, C = chloroform, E = ether, H = hexane, M = methanol and W = water, VS = very soluble, FS = freely soluble, S = soluble, PS = sparingly soluble, SS = slightly soluble, VSS = very slightly soluble and I = insoluble

## 3. SCREENING TECHNIQUES

### 3.1. COLOR TESTS

REAGENT	COLOR PRODUCED
Marquis	Purple to black

### 3.2. CRYSTAL TESTS

REAGENT	CRYSTALS FORMED
Gold chloride in HOAc	Rosettes of various sizes with a rusty color with high birefringence under polarized light radiating from the center outward down the arms. Feathery extensions from the arms are parallel to each other preserved on both sides of the arms.
Platinic chloride in HOAc	Burr-like rosettes of various sizes. Radii from the center resemble pine branches with fine needles. Needles have high birefringence under polarized light.

### 3.3. THIN LAYER CHROMATOGRAPHY

#### Visualization

Acidified potassium permanganate solution

COMPOUND	Relative R <sub>f</sub>	
	System TLC 5	System TLC 6
3,4-methenedioxyethylamphetamine	1.3	1.8
3,4-methylenedioxyamphetamine	1.2	1.5
3,4-methylenedioxydimethylamphetamine	1.1	1.8
<b>3,4-methylenedioxymethamphetamine</b>	<b>1.0</b>	<b>1.0</b>

### 3.4. GAS CHROMATOGRAPHY

#### *Method MDMA-GCSI*

<b>Instrument:</b>	Gas chromatograph operated in split mode with FID
<b>Column:</b>	5% phenyl/95% methyl silicone 30 m x 0.25 mm x 0.25 µm film thickness
<b>Carrier gas:</b>	Hydrogen at 2.0 mL/min
<b>Temperatures:</b>	Injector: 260°C Detector: 270°C Oven program: 1) 90°C initial temperature for 1.0 min 2) Ramp to 295°C at 30°C/min 3) Hold final temperature for 2.6 min
<b>Injection Parameters:</b>	Split Ratio = 50:1, 1 µL injected

Samples are to be dissolved in 4:1 chloroform: methanol and filtered.

COMPOUND	RRT	COMPOUND	RRT
amphetamine	0.58	acetaminophen	1.18
methamphetamine	0.64	caffeine	1.27
safrole	0.76	methyl stearate	1.42
C <sub>14</sub>	0.85	cocaine	1.53
3,4-MDA	0.95	methyl eicosanoate	1.54

<b>3,4-MDMA</b>	<b>1.00 (4.39 min)</b>	tetraphenylethylene	1.69
3,4-MDEA	1.04	heroin	1.80
3,4-MDDMA	1.06		

**Method MDMA-GCS2**

**Instrument:** Gas Chromatograph operated in split mode with FID

**Column:** 50% phenyl/50% methyl silicone 30 m x 0.25 mm x 0.25 µm film thickness

**Carrier gas:** Hydrogen at 2.0 mL/min

**Temperatures:** Injector: 260°C  
 Detector: 270°C  
 Oven program:  
 1) 90°C initial temperature for 1.0 min  
 2) Ramp to 295°C at 30°/min  
 3) Hold final temperature for 2.6 min

**Injection Parameters:** Split Ratio = 50:1, 1 µL injected

Samples are to be dissolved in 4:1 chloroform: methanol and filtered.

<b>COMPOUND</b>	<b>RRT</b>	<b>COMPOUND</b>	<b>RRT</b>
amphetamine	0.60	acetaminophen	1.27
methamphetamine	0.64	caffeine	1.34
safrole	0.78	methyl stearate	1.26
C <sub>14</sub>	0.67	cocaine	1.53
3,4-MDA	0.97	methyl eicosanoate	1.37
<b>3,4-MDMA</b>	<b>1.00 (4.99 min)</b>	tetraphenylethylene	1.72
3,4-MDEA	1.02	heroin	1.97
3,4-MDDMA	1.04		

**Method MDMA-GCS3**

**Instrument:** Gas chromatograph operated in split mode with FID

**Column:** 5% phenyl/95% methyl silicone 5 m x 0.25 mm x 0.25 µm film thickness

**Carrier gas:** Hydrogen:  
 1) Initial pressure of 2.5 psi for 0.10 min  
 2) Ramp to 5.0 psi at 3.41 psi/min  
 3) Hold final pressure for 0.77 min

**Temperature:** Injector: 260°C  
 Detector: 270°C  
 Oven program:  
 1) 90°C initial temperature  
 2) Ramp to 100°C at 10°/min  
 3) Hold final temperature for 0.60 min

**Injection Parameters:** Split Ratio = 50:1, 1 µL injected  
 EZFlash Parameters:  
 1) Time 0 s = 100°C  
 2) Time 6 s = 110°C  
 3) Time 50 s = 310°C  
 4) Time 96 s = 310°C

Samples are to be dissolved in 4:1 chloroform: methanol and filtered.

COMPOUND	RRT	COMPOUND	RRT
amphetamine	0.70	acetaminophen	1.14
methamphetamine	0.74	caffeine	1.22
safrole	0.82	methyl stearate	1.23
C <sub>14</sub>	0.88	cocaine	1.44
3,4-MDA	0.96	methyl eicosanoate	1.34
<b>3,4-MDMA</b>	<b>1.00 (4.99 min)</b>	tetraphenylethylene	1.62
3,4-MDEA	1.03	heroin	1.80
3,4-MDDMA	1.04		

**Method MDMA-GCS4**

**Instrument:** Gas chromatograph operated in split mode with FID

**Column:** 1% phenyl/99% methyl silicone 30 m x 0.25 mm x 0.25 µm film thickness

**Carrier gas:** Hydrogen at 2.0 mL/min

**Temperature:** Injector: 260°C  
 Detector: 270°C  
 Oven program:  
 1) 90°C initial temperature for 1.0 min  
 2) Ramp to 295°C at 30 degrees/min  
 3) Hold final temperature for 2.6 min

**Injection Parameters:** Split Ratio = 50:1, 1 µL injected

COMPOUND	RRT	COMPOUND	RRT
amphetamine	0.53	acetaminophen	1.19
methamphetamine	1.65	caffeine	1.28
safrole	0.72	methyl stearate	1.53
C <sub>14</sub>	0.91	cocaine	1.60
3,4-MDA	0.94	methyl eicosanoate	1.67
<b>3,4-MDMA</b>	<b>1.00 (4.36 min)</b>	tetraphenylethylene	1.78
3,4-MDEA	1.05	heroin	1.89
3,4-MDDMA	1.08		

#### 4. SEPARATION TECHNIQUES

MDMA base, hydrochloride, or phosphate can be separated from the matrix by solvent extraction using the solubility data found in [Section 2.2](#).

#### 5. QUANTITATIVE PROCEDURES

##### 5.1. GAS CHROMATOGRAPHY

###### Method MDMA-GCQ1

Internal Standard Stock Solution:

1.0 mg/mL *n*-butylamphetamine HCl in chloroform.

*Standard Solution Preparation:*

Prepare a standard solution of **MDMA HCl at 0.4 mg/mL in chloroform.**

*Sample Preparation:*

Accurately weigh out 50 mg of sample into a 25 mL volumetric flask and dilute with water to the mark. Take a 2 mL aliquot of the solution, add 3 mL of I.S. and 2-3 mL of 0.5 M KOH. Shake. Separate layers and extract twice more with 2-3 mL each time of chloroform. Combine fractions, dry over sodium sulfate and dilute to total volume of 10 mL. Treat the standard in the same fashion as the sample prior to analysis.

*Instrument:* Gas chromatograph operated in split mode with FID

*Column:* **DB-1, 30 m x 0.25 mm x 0.25 µm film thickness**

*Carrier gas:* **Hydrogen at 1.3 mL/min**

*Make-Up gas:* Nitrogen at 40.0 mL/min

*Temperatures:* **Injector: 230°C**  
**Detector: 280°C**  
**Oven Program:**  
**1) 150°C initial temperature 2 min**  
**2) Ramp to 190°C at 5°/min**  
**3) Hold final temperature for 1.0 min**

*Injection Parameters:* Split Ratio = **20:1**, 1 µL injected

*Typical Retention Time:* 3,4-MDMA: **5.10 min**  
*n*-butylamphetamine HCl: **3.92 min**

*Linear Range:* **0.06 mg/mL to 2.0 mg/mL**

*Repeatability:* RSD less than 2.0%

*Correlation Coefficient:* **0.9998**

*Accuracy* Error less than 5%

COMPOUND	RRT	COMPOUND	RRT	COMPOUND	RRT
methylbenzylamine	0.35	methyl paraben	0.77	caffeine	1.86
P-2-P	0.38	salicylamide	0.77	antipyrine	2.00
amphetamine	0.39	penicillin	0.78	benzphetamine	2.04

nicotinic acid	0.42	phenmetrazine	0.81	diphenhydramine	2.14
phentermine	0.42	MDP-2-P	0.84	aminopyrine	2.26
methamphetamine	0.44	phendimetrazine	0.86	doxylamine	2.31
fenfluramine	0.48	MDA	0.87	palmitic acid	2.45
ethylamphetamine	0.49	MDMA	1.00 (5.1 min)	phthalic acid	2.45
dimethylamphetamine	0.50	aminorex	1.05	dipyron	2.51
safrole	0.55	methyl aminorex	1.05	procaine	2.66
salicylic acid	0.56	MDEA	1.13	eicosane	2.67
cathine	0.59	ibuprofen	1.24	dextromethorphan	3.12
phenylpropanolamine	0.59	MBDB	1.26	strychnine	3.17
methcathinone	0.60	hexadecane	1.28	phenyl-2-naphthalene	3.27
nicotinamide	0.62	glycerol glycolate	1.30	amitriptyline	3.34
chlorpheniramine	0.65	acetaminophen	1.35	scopolamine	3.71
chloroephedrine	0.66	MMDA	1.38	tetracosane	4.07
pseudoephedrine	0.66	phenacetin	1.41	chlordiazepoxide	4.31
ephedrine	0.68	chloro-MDMA	1.49	quinine	5.23
butylamphetamine	0.77	methylphenidate	1.63		

## 5.2. HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

### *Method MDMA-LCQ1*

#### *Standard Solution Preparation:*

Prepare a standard solution of MDMA at approximately 0.5 mg/mL using water, buffer, or methanol.

#### *Sample Preparation:*

Accurately weigh an amount of sample into an appropriate volumetric or Erlenmeyer flask and dilute so that the final MDMA concentration is approximately that of the standard solution.

#### *Instrument:*

High performance liquid chromatograph equipped with diode array

#### *Column:*

5 µm Phenomenex Luna, 150 mm x 3.2 mm at 35°C

#### *Detector:*

UV, 210 nm



**Flow:** 1.0 mL/min

**Injection Volume:** 5 µL

**Buffer:** 4000 mL distilled water, 22.5 mL phosphoric acid, adjust to pH 2.2-2.3 with triethanolamine (approx. 22 mL)

**Mobile Phase:** Buffer:acetonitrile 90:10

**Typical Retention Time:** 3,4-MDMA: 10.54 min

**Linear Range:** 0.05 mg/mL – 2 mg/mL

**Repeatability:** RSD less than 0.5%

**Correlation Coefficient:** 0.9999

**Accuracy:** Error less than 5%

COMPOUND	RRT	COMPOUND	RRT
phenylpropanolamine	0.60	methyl aminorex	1.01
methyl benzylamine	0.62	phentermine	1.02
cathine	0.63	chloroephedrine	1.03
doxylamine	0.69	ethylamphetamine	1.05
dipyrone	0.70	MDP-2-P	1.05
ephedrine	0.72	lidocaine	1.07
methcathinone	0.73	caffeine	q
pseudoephedrine	0.73	MDEA	1.13
amphetamine	0.84	phenyl-2-naphthalene	1.13
theophylline	0.87	phthalic acid	1.13
methapyrilene	0.89	strychnine	1.14
phenmetrazine	0.89	MMDA	1.17
methamphetamine	0.91	MBDB	1.25
phendimetrazine	0.91	salicylamide	1.27

COMPOUND	RRT	COMPOUND	RRT
scopolamine	0.92	acetaminophen	1.29
MDA	0.93	chloro-MDMA	1.37
quinine	0.96	methylphenidate	1.38
saccharin	0.96	glycerol glycolate	1.48
dimethylamphetamine	0.97	chlorpheniramine	1.55
MDMA	1.00 (10.54 min)	aspirin	1.81
		chlordiazepoxide	1.87

### 5.3. CAPILLARY ELECTROPHORESIS

#### *Method MDMA-CEQ1*

##### *Internal Standard Stock Solution:*

0.50 mg/mL *n*-butylamphetamine in 50 mM sodium phosphate at pH 7.0.

##### *Standard Solution Preparation:*

Accurately weigh and prepare a standard solution of 3,4-methylenedioxymethamphetamine hydrochloride at approximately 0.8 mg/mL using the internal standard stock solution.

##### *Sample Preparation:*

Accurately weigh an amount of sample into a volumetric flask and dilute with internal standard stock solution. If necessary dilute the sample so the final concentration approximates the standard concentration or falls within the linear range. Filter sample with 0.45-micron filter.

**Mode:** Cyclodextrin system analysis

**Column:** 49 cm x 52 µm fused silica capillary

**Run Buffer:** 10 mM gamma-highly sulfated cyclodextrin in 50 mM sodium phosphate at pH 7.0

**Detector:** UV, 210 nm

**Voltage:** 12 kV

**Temperature:** 30°C air cooled

**Injection:** 1 sec hydrodynamic at 50 mbar/s

<b>Run Time:</b>	17 min
<b>Rinse Time:</b>	2.0 min
<b>Linear Range:</b>	0.02 - 1.00 mg/mL
<b>Repeatability:</b>	RSD of area less than 1.5%
<b>Correlation Coefficient:</b>	0.999
<b>Accuracy:</b>	Error less than 5%

COMPOUND	RRT	COMPOUND	RRT
d-methamphetamine	0.66	l-pseudoephedrine	0.98
d-ephedrine	0.74	<b>MDMA*</b>	<b>1.00 (11.04 min)</b>
MDA*	0.80	l-ephedrine	1.09
cathine	0.85	MDEA*	1.12
l-methamphetamine	0.89	<b>MDMA*</b>	<b>1.19</b>
d-amphetamine	0.94	l-norephedrine	1.32
d-norephedrine	0.94	l-amphetamine	1.34
d-pseudoephedrine	0.97	MDA*	1.36
		MDEA*	1.49

### **Method MDMA-CEQ2**

#### *Internal Standard Stock Solution:*

1.0 mg/mL *n*-butylamphetamine in 3.8 mM phosphate buffer (pH 2.5)

#### *Standard Solution Preparation:*

Weigh an appropriate amount of standard 3,4-MDMA HCl into a volumetric flask to obtain a final concentration of approximately 0.08 mg/mL. Pipette appropriate amount of internal standard solution to obtain a final concentration of 0.1 mg/mL. Dilute to volume with injection solvent. Filter approximately 1.0 mL of solution with regenerated cellulose 0.45 µm 25 mm filter into a 2.0 mL glass vial (Agilent part number 5182-0567.) Make sure there are no air bubbles on bottom of glass vial. Cap vial with polypropylene cap (Agilent part number 5182-9697.)

#### *Sample Preparation:*

Weigh an appropriate amount of sample into a volumetric flask so that the final phenethylamine concentration is approximately that of the standard solution. Pipette appropriate amount of internal standard solution to obtain a final concentration of 0.1 mg/mL. Dilute to volume with injection solvent. Sonicate for 15 minutes. Filter approximately 1.0 mL of solution with regenerated cellulose 0.45 µm 25 mm filter into a 2.0 mL glass vial (Agilent part number 5182-0567.) Make sure there are no air bubbles on bottom of glass vial. Cap vial with polypropylene cap (Agilent part number 5182-9697.)

<b>Mode:</b>	HP 3D instrument operated in CE mode Coated Capillary Mode
<b>Column:</b>	50 µm i.d. x 32.2 cm (23.7 cm length to detector)
<b>Run Buffer:</b>	Celixir Reagent B, pH 2.5 (MicroSolv CE)
<b>Detector:</b>	UV, 195 nm
<b>Voltage:</b>	10 kV
<b>Temperature:</b>	15°C
<b>Injection:</b>	50 mbar x 2 s followed by water at 35 mbar
<b>Run Time:</b>	6 min
<b>Rinse Time:</b>	2 min
<b>Linear Range:</b>	0.02 - 1.00 mg/mL
<b>Repeatability:</b>	RSD <1.6%
<b>Correlation Coefficient:</b>	1.0
<b>Accuracy:</b>	Error less than 3.2%

COMPOUND	RRT	COMPOUND	RRT
doxylamine	0.765	ephedrine	0.932
chlorpheniramine	0.784	phenylephrine	0.951
quinine	0.804	MDEA	0.961
β-phenethylamine	0.807	ketamine	0.962

COMPOUND	RRT	COMPOUND	RRT
chlorquinine	0.812	phenyltoloxamine	0.971
nicotinamide	0.836	<b><i>n</i>-butylamphetamine</b>	<b>1.0(4.6 min)</b>
amphetamine	0.868	dextromethorphan	1.00
methamphetamine	0.883	lidocaine	1.03
procaine	0.883	benzocaine	1.25
MDA	0.900	acetaminophen	2.11
norpseudoephedrine	0.906	caffeine	2.14
MDMA	0.914	guaifenesin	2.14
norephedrine	0.917	P2P	2.24
pseudoephedrine	0.919	DMSO (neutral marker)	2.40
tetracaine	0.927	aspirin	2.71

#### 5.4. NUCLEAR MAGNETIC RESONANCE

##### *Method MDMA-NMRI*

*Solvents:* Deuterium Oxide (D<sub>2</sub>O) containing DSS or TSP for 0 PPM reference.

*Internal Standard Stock Solution (ISSS):* 5 mg/mL Maleic Acid (accurately weighed) in deuterium oxide (D<sub>2</sub>O) containing DSS or TSP for 0 ppm reference.

*Sample Preparation:* Accurately weigh an amount of sample, usually 10-30 mg, into a capped test tube and accurately add a volume, normally 1.0 mL, of the ISSS. Vortex the sample for several seconds. If insolubles are present, add 1.0 mL D<sub>2</sub>O (not containing maleic acid or the reference compound), vortex and sonicate 15 minutes. Vortex the sample and filter if necessary. Place in NMR sample tube.

*Instrument:* Varian Mercury 400 MHz with proton detection probe NMR Spectrometer

*Pulse Width:* 10 μs or 90°(whichever is less)

<b><i>Spectral Width (SW)</i></b>	at least containing –3 ppm through 13 ppm
<b><i>Number of Scans:</i></b>	multiple of 4 (greater to enhance signal to noise (S/N))
<b><i>Delay between Pulses:</i></b>	45 s
<b><i>Shimming:</i></b>	automatic gradient shimming of Z1-4 shims
<b><i>Total run time/sample:</i></b>	6 min (NT=4) -14 min (NT=16)
<b><i>Uniformity within spectral width:</i></b>	0.3% RSD (-0.6 to 11.4 PPM)
<b><i>Run Time:</i></b>	6 min
<b><i>Linear Range:</i></b>	0.6 mg/mL-60 mg/mL
<b><i>Repeatability:</i></b>	< 4%
<b><i>Correlation Coefficient:</i></b>	1.0
<b><i>Accuracy:</i></b>	< 3%

<b>Compound</b>	<b>MW</b>	<b>Solvent</b>	<b>Internal Standard</b>	<b>Solubility (mg/mL)</b>	<b>Signals used for quantitation (position in ppm with number of protons). Signals in bold and underlined are preferred if other numbers present.</b>	<b>Decomposition rate (%/hour)</b>
MDMA HCl	229.71	D <sub>2</sub> O	maleic acid	>30	6.7-6.9 (m)(3), 6.0 (s)(2), 3.5 (sextet)(1), 3.0dd(1), 2.8dd(1), 2.7 (s)(3), 1.3 (d)(3)	<0.1
MDMA phosphate	291.24	D <sub>2</sub> O	maleic acid	>19	6.7-6.9 (m)(3), 6.0 (s)(2), 3.5 (sextet)(1), 3.0dd(1), 2.8dd(1), 2.7 (s)(3), 1.3 (d)(3)	<0.1

## 6. QUALITATIVE DATA

See spectra on the following pages for [FT-IR](#), [Vapor Phase IR](#), [FT-Raman](#), [Mass Spectrometry](#), and [Nuclear Magnetic Resonance](#).

## **7. REFERENCES**

Coates, J., and Reffner, J., "Visualization of Micro-ATR Infrared Spectroscopy," *Spectroscopy*, Vol. 14, #4, April 1999.

Clarke, E.G.C., *Isolation and Identification of Drugs*, 2nd Edition, The Pharmaceutical Press, 1986.

Galichat, Laurent Y., *Clarke's Analysis of Drugs and Poisons*, Volume 2, p. 1256, Pharmaceutical Press, 2004.

Budavari, S., *The Merck Index*, 13th Edition, Merck and Co., Inc., 2001.


## **8. ADDITIONAL RESOURCES**

[Forendex](#)


[Wikipedia](#)

---

FTIR (KBr): 3,4-Methylenedioxyamphetamine Hydrochloride  
50 scans, 1 nm resolution, 5 mg/150 mg




FTIR (diamond ATR 3 bounce): 3,4-Mehtylenedioxyamphetamine Base







FTIR (1 bounce ATR): MDMA phosphate  
32 scans, resolution 4 cm<sup>-1</sup>




IR (Vapor Phase): 3,4-Methylenedioxyamphetamine Lot # A150B  
2 mg/mL in CH<sub>3</sub>OH




FT-RAMAN: 3,4-Methylenedioxyamphetamine Base  
Extracted from MDMA HCl, Lot #A150B, 32 scans, 4 cm<sup>-1</sup> resolution




FT-RAMAN: 3,4-Methylenedioxyamphetamine HCl  
Lot # A150B, 32 scans, 4 cm<sup>-1</sup> resolution




FT-RAMAN: 3,4-Methylenedioxyamphetamine Phosphate Lot # 2 TDM-275-01  
32 scans, 4 cm<sup>-1</sup> resolution




Mass Spectrometry (EI): 3,4-Methylenedioxyamphetamine




### Mass Spectrometry (CI): 3,4-Methylenedioxyamphetamine




### <sup>1</sup>H NMR: MDMA base in CDCl<sub>3</sub> with TMS 400 MHz Extracted from MDMA HCl – Lot # A150B




ppm 6.73 (d, J=7.83 Hz, 1 H) 6.68 (d, J=1.17 Hz, 1 H) 6.63 (dd, J=7.83, 1.17 Hz, 1 H) 5.92 (s, 2 H) 2.67 - 2.78 (ddq, J=7.20, 6.30, 6.30, 6.30, 6.30 Hz, 1 H) 2.61 (dd, J=13.50, 7.24 Hz, 1 H) 2.54 (dd, J=13.30, 6.26 Hz, 1 H) 2.39 (s, 3 H) 1.04 (d, J=6.26 Hz, 3 H)




<sup>13</sup>C NMR: MDMA Base  
 Extracted from MDMA HCl – Lot #A 150B




<sup>1</sup>H NMR: MDMA Phosphate in D2O with TSP 400 MHz  
Lot # 2 TDM-275-01




ppm 6.88 - 6.92 (d, J=8.00 Hz, 1 H) 6.86 (d, J=1.37 Hz, 1 H) 6.80 (dd, J=8.00, 1.40 Hz, 1 H) 5.98 (s, 2 H)  
3.44 - 3.55 (ddq, J=7.50, 6.70, 6.70, 6.50 Hz, 1 H) 2.99 (dd, J=13.90, 6.50 Hz, 1 H) 2.85 (dd, J=13.90,  
7.60 Hz, 1 H) 2.70 (s, 3 H) 1.28 (d, J=6.65 Hz, 3 H)





<sup>13</sup>C NMR: MDMA Phosphate in D2O with TSP Lot # 2 TDM-275-01



<sup>1</sup>H NMR: MDMA Phosphate in CD<sub>3</sub>OD with TMS Lot #2 TDM-275-01, 400 MHz




ppm 6.79 (d, J=0.98 Hz, 1 H) 6.78 (d, J=8.02 Hz, 1 H) 6.73 (dd, J=8.00, 1.20 Hz, 1 H)  
5.93 (s, 2 H) 3.29 - 3.40 (m, 1 H) 3.08 (dd, J=13.50, 5.09 Hz, 1 H) 2.69 (s, 3 H) 2.67 (dd,  
J=13.30, 9.60 Hz, 1 H) 1.22 (d, J=6.46 Hz, 3 H)






1H NMR: MDMA HCl Lot # A150B  
with maleic acid as internal standard in D<sub>2</sub>O with TSP, 400 MHz




ppm 6.88 (d, J=7.92 Hz, 1 H) 6.84 (d, J=1.66 Hz, 1 H) 6.76 - 6.81 (dd, J=7.90, 1.80 Hz, 1 H) 5.97 (s, 2 H) 3.41 - 3.54 (ddq, J=7.70, 6.70, 6.70, 6.50 Hz, 1 H) 2.93 - 3.02 (dd, J=14.00, 6.50 Hz, 1 H) 2.83 (dd, J=14.00, 7.70 Hz, 1 H) 2.70 (s, 3 H) 1.27 (d, J=6.65 Hz, 3 H). Maleic acid 6.40 (s, 2H).


1H NMR: MDMA base in CD<sub>3</sub>OD with TMS  
Extracted from MDMA HCl - Lot #A150B, 400 MHz




ppm 6.69 - 6.74 (d, J=7.83 Hz, 1 H) 6.67 (d, J=1.37 Hz, 1 H) 6.62 (dd, J=7.80, 1.40 Hz, 1 H) 5.88 (s, 2 H) 2.65 - 2.76 (m, 2 H) 2.44 (dd, J=15.30, 9.40 Hz, 1 H) 2.34 (s, 3 H) 1.00 (d, J=6.06 Hz, 3 H)




$^1\text{H}$  NMR: MDMA HCl in  $\text{CD}_3\text{OD}$  Lot # A150B  
400 MHz



ppm 6.80 (d,  $J=1.60$  Hz, 1 H) 6.79 (d,  $J=8.02$  Hz, 1 H) 6.74 (dd,  $J=8.02, 1.56$  Hz, 1 H) 5.93 (s, 2 H) 3.36 - 3.48 (ddq,  $J=9.40, 6.50, 6.50, 5.30$  Hz, 1 H) 3.08 (dd,  $J=13.50, 5.28$  Hz, 1 H) 2.71 (dd,  $J=13.30, 9.40$  Hz, 1 H) 1.25 (d,  $J=6.46$  Hz, 3 H)



<sup>13</sup>C NMR: MDMA HCl in CD<sub>3</sub>OD Lot # A150B



\*Optical isomers standards for these compounds were unavailable.

\*\*\*No Data Available